Coverage guidelines effective March 1, 2019

Anthem Blue Cross and Blue Shield in Virginia and our affiliate, HealthKeepers, Inc., will implement the following new and revised coverage guidelines effective March 1, 2019.  These guidelines impact all our products – with the exception of Anthem HealthKeepers Plus (Medicaid), the Commonwealth Coordinated Care Plus (Anthem CCC Plus) plan, Medicare Advantage, and the Blue Cross and Blue Shield Service Benefit Plan (also called the Federal Employee Program or FEP).  Furthermore, the guidelines were among those recently approved at the Medical Policy and Technology Assessment Committee meeting held on September 13, 2018. 

 

SPECIAL NOTES:

 

The services addressed in these coverage guidelines in this section and in the attachment under “Article Attachments” on the right will require authorization for all of our products offered by HealthKeepers, Inc. with the exception of Anthem HealthKeepers Plus (Medicaid) and the Commonwealth Coordinated Care Plus (Anthem CCC Plus).  Other exceptions are Medicare Advantage and the Federal Employee Program.

A pre-determination can be requested for our PPO products.

 

Services related to specialty pharmacy drugs (non-cancer related) require a medical necessity review, which includes site of care criteria, as outlined in the applicable coverage or clinical UM guideline listed.

The following guidelines are addressed in this December 2018 edition (see also attachment under "Article Attachments" on the right):

 

• Measurement of Serum Concentrations of Monoclonal Antibody Drugs and Antibodies to Monoclonal Antibody Drugs (LAB.00030)

 

• Allogeneic, Xenographic, Synthetic, and Composite Products for Wound Healing and Soft Tissue Grafting (SURG.00011)

 

• Biofeedback and Neurofeedback (MED.00125)

 

• Enzyme Replacement Therapy for Gaucher Disease (CG-DRUG-08)